Cervical cancer CC is the most common malignant tumor in the female reproductive system, seriously endangering women's health and life, and is one of the leading causes of death for women worldwide.Globally, HPV causes about 85% of cervical cancers and about 60% of oropharyngeal cancers, causing more than 500,000 cancers each year.ctDNA is a potential biomarker because it contains tumor-specific genetic and epigenetic abnormalities that can be used in cancer diagnosis and prognosis prediction.MRD is considered a promising prognostic marker that can be used to identify individuals at increased risk of recurrence and individuals who may benefit from treatment.The expression level of MRD and plasma HPV before and after radiotherapy and chemotherapy for cervical cancer was analyzed by liquid biopsy ctDNA detection technology, which predicted the efficacy of cervical cancer radiotherapy and chemotherapy, which was helpful for monitoring and estimating the risk of disease recurrence after cervical cancer radiotherapy and chemotherapy, and verified the expression of MRD and plasma HPV as the basis for adjuvant chemotherapy after cervical cancer radiotherapy and the basis for optimal chemotherapy time node selection.
Age: ≥ 18 years old, ≤ 75 years old.
Pathological histologic confirmation of cervical cancer.
Imaging or PET/CT examination can be performed to understand the tumor and complete all follow-up.
Measurable lesions before treatment.
Those who are allergic to rubber products.
Those with severe acute infection and uncontrolled or purulent and chronic infection wounds that do not heal, chronic hepatitis B active stage, active tuberculosis, syphilis outbreak and AIDS.
Patients with pre-existing severe heart disease, including: congestive heart failure, uncontrollable high-risk arrhythmia, unstable angina, myocardial infarction, severe valvular heart disease, and intractable hypertension.
Those with neurological or psychiatric diseases or mental disorders that are not easy to control, poor compliance, unable to cooperate with and describe treatment responses, uncontrolled primary brain tumors or central nervous system metastases, and those with obvious cranial hypertension signs or neuropsychiatric symptoms.
Diagnosed cervical cancer patients who initially visited Guizhou Provincial People's Hospital from November 2022 to November 2024
Cohort
Prospective
Concurrent chemoradiotherapy
Other interventionConcurrent chemoradiotherapy
Expression levels of MRD
Blood collected by patients prior to concurrent chemoradiotherapy were tested to observe the expression levels of MRD
Positive expression of plasma HPV
Tissue samplescollected by patients prior to concurrent chemoradiotherapy were tested to observe the positive expression of plasma HPV
Expression levels of MRD
Blood collected in concurrent chemoradiotherapy were examined to observe the expression levels of MRD
Positive expression of plasma HPV
Tissue samples collected in concurrent chemoradiotherapy were examined to observe the positive expression of plasma HPV
Click on the lead sponsor to view all of their trials.
